Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.61
(
-1.04%
)
Bitcoin
74,549.01
(
0.82%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 151846

Tuesday, 11/06/2012 8:02:32 PM

Tuesday, November 06, 2012 8:02:32 PM

Post# of 257253
Reuters chimes in on Xeljanz approval—price is ~$25K*/year:

http://www.reuters.com/article/2012/11/06/pfizer-arthritis-idUSL1E8M6D8820121106

Note: The FDA approved only the 5mg dose, not the 10mg dose that was also tested in phase-3 trials. However, the non-approval of the 10mg dose is (IMO) less consequential than the broadness of the second-line label (i.e. no requirement for prior treatment with a TNF-alpha drug).

*This was subsequently confirmed by PFE.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now